COPD: Emerging Trends in Treatment Options
Sponsored by The American College of Chest Physicians
Program Overview
As chronic obstructive pulmonary disease (COPD) becomes more prevalent and associated mortality rates continue to rise, the need for better treatment options and different delivery systems is high. This podcast will provide the most current information regarding diagnostic tools and treatment opportunities. Presenters will also review advanced studies and ideas for future treatments and other pharmacologic options.
Educational Objectives
- Evaluate new diagnostic tools and treatment options.
- Evaluate and discuss future COPD treatment options and studies.
- Compare and contrast different delivery systems in COPD.
Needs Statement
The overall approach to managing stable COPD should be characterized by an increase in treatment, depending on the severity of the disease and the clinical status of the patient. The podcast will provide the most current information regarding diagnostic tools and treatment opportunities.
Faculty
Neil R. MacIntyre, MD, FCCP
Clinical Chief in the Division of Pulmonary, Allergy and
Critical Care and Professor in the Department of
Medicine at Duke University
Durham, NC
Stephen C. Lazarus, MD
Division of Pulmonary & Critical Care Medicine
Cardiovascular Research Institute
Professor of Medicine at the University of California
San Francisco, CA
Fernando J. Martinez, MD, MS, FCCP
Professor of Internal Medicine at the University of Michigan
University of Michigan Health System
Ann Harbor, MI
Agenda and Faculty
Trends in the Diagnosis and Treatment of Patients with COPD
Neil R. MacIntyre, MD, FCCP
New Pharmacologic Options and Products Available for COPD
Stephen C. Lazarus, MD
Optimal Drug Delivery Options
Fernando J. Martinez, MD, MS, FCCP
Release Date: April, 2007
CME Expiration Date: April 30, 2008
Estimated Completion Time- 2 hours
Participants will view a podcast of the entire satellite symposium. There will be three presentations.
Participants will view this podcast then participate in an online evaluation form.
Accreditation Statement:
The American College of Chest Physicians (ACCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Chest Physicians designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Anyone who attended “COPD: Emerging Trends in Treatment Options” session at CHEST 2007 when this content was presented, and already claimed CME for this presentation, cannot claim CME from this enduring product.
Disclosure Statement:
The ACCP remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair, the Continuing Education Committee, or the Conflict of Interest Review Committee to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available on-site during all educational activities”.
Neil MacIntyre, MD, FCCP
Speaker Bureau: Pfizer, Sepracor and GSK
Fernando J. Martinez, MD
Consultant fee, speaker bureau, advisory committee: ALTANA Pharma, Boehringer Ingelheim, GlaxoSmithKline, Pfizer and sanofi-aventis
The following presenter has indicated to the ACCP that no significant relationships exist with any company/organization whose products or services may be discussed during their presentation.
Stephen C. Lazarus, MD
NHLBI Asthma Clinical Research Network
NHLBI COPD Clinical Research Network
The following presenter has disclosed that he may be discussing information about a product/procedure/technique that is considered research and is not yet approved for any purpose:
Stephen C. Lazarus, MD
Potential new B-agonist, anti-cholmergics, PDE4 inhalers, anti-oxidants, anti-cytokiues, protease inhibitors, HDAE activators
Disclaimer Statement:
The American College of Chest Physicians (“ACCP”) and its officers, regents, executive committee, members, and employees are not responsible in any capacity for, do not warrant and expressly disclaim all liability for any content whatsoever in, and in particular without limiting the foregoing, the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any ACCP publication, all such responsibility being solely that of the authors or the advertisers, as the case may be. All responsibility and liability for any of the foregoing for any claimed injury or damages to any person or property alleged to have resulted from any of the foregoing, whether based on warranty, contract, tort, or any other legal theory, and whether or not any claimant was advised of the possibility of such damages, is expressly disclaimed and denied by ACCP, its officers, regents, executive committee, members, and employees. For any possible specific medical condition whatsoever, all persons should consult a qualified health-care professional of their own choice for advice.
Copyright 2007 by the American College of Chest Physicians and its Licensors
Instructions for Obtaining CME credit:
The American College of Chest Physicians designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Anyone who attended “COPD: Emerging Trends in Treatment Options” session at CHEST 2007 when this content was presented, and already claimed CME for this presentation, cannot claim CME from this enduring product.
1) Go to www.chestnet.org and click on the “CME Certificates” bar highlighted in red
2) Enter your ACCP ID number and click submit, OR, if you do not have an ACCP ID number, click on link “ Need to Create an Account”
3) Under “Available CME” find the product code 6665, and click the “CME” link to the right of the program title
4) If prompted for one, enter the CME Access Code provided to you EXACTLY as it appears:
211871.6665.POD
5) Complete any required post-test and/or survey
6) Print out the CME certificate found under “Your Current CME History”
7) If you encounter any problems or have questions, please send an email to CME@chestnet.org or contact the ACCP CME verification mailbox at 1-847-498-8376
Supported by an educational grant from Sepracor.
Click Here To Download the Presentations
|
